You are here

Herzuma Approved for Treatment of Breast Cancer

New Biosimilar Provides Broader Treatment Options for Patients

The FDA has approved another biosimilar for the adjuvant treatment of HER2 overexpressing, node-positive or node-negative breast cancer. In addition, this biosimilar Herzuma (trastuzumab-pkrb, Celltrion, South Korea, and Teva Pharmaceutical, Israel) is approved as part of a first-line treatment for metastatic breast cancer combined with chemotherapy.

Common adverse events associated with the use of trastuzumab-pkrb for treatment of HER2-positive breast cancers include diarrhea, headache, chills, nausea, fever, infection, insomnia, congestive heart failure, cough and rash. Serious adverse effects can include worsening of chemotherapy-induced neutropenia.

Like its reference product trastuzumab (Herceptin, Genentech), trastuzumab-pkrb carries a boxed warning about elevated risks for cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.

Source: Biospace.com, December 17, 2018

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time